Tarsus Pharmaceuticals Inc. (TARS)
NASDAQ · Healthcare
Tarsus Pharmaceuticals Inc. Operating Income 2020–2025
Tarsus Pharmaceuticals Inc. annual/quarterly operating income history and growth rate from 2020 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Tarsus Pharmaceuticals Inc. operating income for the quarter ending March 31, 2026 was -6.1 M, a 76.70% decrease year-over-year.
- Tarsus Pharmaceuticals Inc. operating income for the twelve months ending March 31, 2026 was -69.1 M, a 49.58% decrease year-over-year.
- Tarsus Pharmaceuticals Inc. annual operating income for 2025 was -71.0 M, a 41.14% decrease from 2024.
- Tarsus Pharmaceuticals Inc. annual operating income for 2024 was -120.6 M, a 15.78% decrease from 2023.
- Tarsus Pharmaceuticals Inc. annual operating income for 2023 was -143.2 M, a 128.28% increase from 2022.
- Tarsus Pharmaceuticals Inc. annual operating income for 2022 was -62.7 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Tarsus Pharmaceuticals Inc. Operating Income — FAQ
Tarsus Pharmaceuticals Inc. (TARS) operating income over the last 6 years — annual and quarterly figures with year-over-year growth and charts.
What is Tarsus Pharmaceuticals Inc.'s operating income?
Tarsus Pharmaceuticals Inc. (TARS) reported operating income of -$71M for fiscal 2025.
Where can I see TARS's operating income history?
The chart and table above show Tarsus Pharmaceuticals Inc.'s operating income by year and by quarter, including the growth rate.